OR WAIT null SECS
© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
September 24, 2021
Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.
Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.
Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations.
September 20, 2021
Effective October 1, 2021, CMS will reimburse for the infusion product when dispensed in the outpatient setting.
September 16, 2021
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
September 15, 2021
The plan will cover administration of the booster for those with cancer or who are immunocompromised.
September 14, 2021
Alinia and Sutent have been removed from the drug lists because of the introduction of generic therapies.
Real-world data show Erleada prolonged survival in both metastatic and non-metastatic castration-sensitive prostate cancer.
September 09, 2021
Investigators found patients with COPD taking Anoro Ellipta had low overall on-treatment exacerbation rates, which can reduce medical costs due to increased adherence to therapy.
September 07, 2021
ICER’s updated analysis uses observational, real-world data for three therapies — Takhzyro, Haegarda, and Cinryze.